Invention Grant
- Patent Title: Dihydropyridinone MGAT2 inhibitors for use in the treatment of metabolic disorders
-
Application No.: US15123791Application Date: 2015-03-05
-
Publication No.: US09701672B2Publication Date: 2017-07-11
- Inventor: Wei Meng , Guohua Zhao
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Jing G. Sun
- International Application: PCT/US2015/018874 WO 20150305
- International Announcement: WO2015/134701 WO 20150911
- Main IPC: C07D409/14
- IPC: C07D409/14 ; C07D401/14 ; C07D401/04 ; C07D409/04 ; C07D417/14 ; A61K31/4436 ; A61K31/4439 ; A61K31/444 ; A61K31/506 ; A61K45/06
Abstract:
The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
Public/Granted literature
- US20170015653A1 DIHYDROPYRIDINONE MGAT2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS Public/Granted day:2017-01-19
Information query
